Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Paul A Cohen, Aime Powell, Steffen Böhm, C Blake Gilks, Colin JR Stewart, Tarek M Meniawy, Max Bulsara, Stefanie Avril, Eleanor C Brockbank, Tjalling Bosse, Gustavo Rubino de Azevedo Focchi, Raji Ganesan, Rosalind M Glasspool, Brooke E Howitt, Hyun-Soo Kim, Jung-Yun Lee, Nhu D Le, Michelle Lockley, Ranjit Manchanda, Trupti Mandalia Show all
Gynecologic Oncology | Published : 2019
OBJECTIVE: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. METHODS: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3-4 NACT cycles and >6-months follow..View full abstract
Awarded by Cancer Research UK